Freenome (FRNM) Stock Overview

Operates as a biotechnology company focused on developing blood-based tests for early cancer detection using artificial intelligence and multiomics technology. More details

FRNM fundamental analysis
Snowflake Score
Valuation	0/6
Future Growth	0/6
Past Performance	0/6
Financial Health	0/6
Dividends	0/6

Risk Analysis

Has not reported any financial data

Shareholders have been substantially diluted in the past year

FRNM Community Fair Values

Create Narrative

See what others think this stock is worth. Follow their fair value or set your own to get alerts.

NEW480,992 members

Join community and earn perks

Gain real feedbackFrom our editorial team, personally. Not silence.

Grow your followingReal investors. The kind who actually invest, not scroll past.

Unlock free accessFree premium subscription for consistent and quality authors.

Learn more Create Narrative

480,992 investors already sharing narratives

View all narratives

Freenome, Inc. Competitors

Price History & Performance

Summary of share price highs, lows and changes for Freenome
Historical stock prices
Current Share Price	US$12.20
52 Week High	US$14.47
52 Week Low	US$9.95
Beta	0
1 Month Change	10.71%
3 Month Change	7.30%
1 Year Change	15.09%
3 Year Change	n/a
5 Year Change	n/a
Change since IPO	21.39%

Recent updates

Shareholder Returns

	FRNM	US Life Sciences	US Market
7D	2.5%	0.6%	-2.0%
1Y	15.1%	13.0%	15.1%

Return vs Industry: FRNM exceeded the US Life Sciences industry which returned 10.2% over the past year.

Return vs Market: FRNM underperformed the US Market which returned 16.4% over the past year.

Price Volatility

Is FRNM's price volatile compared to industry and market?
FRNM volatility
FRNM Average Weekly Movement	4.8%
Life Sciences Industry Average Movement	8.7%
Market Average Movement	7.1%
10% most volatile stocks in US Market	16.1%
10% least volatile stocks in US Market	3.2%

Stable Share Price: FRNM has not had significant price volatility in the past 3 months compared to the US market.

Volatility Over Time: FRNM's weekly volatility (5%) has been stable over the past year.

About the Company

Founded	Employees	CEO	Website
2014	n/a	Aaron Elliott	www.freenome.com

Freenome, Inc. operates as a biotechnology company focused on developing blood-based tests for early cancer detection using artificial intelligence and multiomics technology. The company develops and provides blood-based tests for early cancer detection, including a test for colorectal cancer screening. It offers a multiomics platform that combines computational biology, machine learning, and multiple data types to identify biomarkers and detect various cancers.

Freenome, Inc. Fundamentals Summary

How do Freenome's earnings and revenue compare to its market cap?
FRNM fundamental statistics
Market cap	US$323.09m
Earnings (TTM)	US$0
Revenue (TTM)	n/a

n/a

P/E Ratio

n/a

P/S Ratio

Is FRNM overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
FRNM income statement (TTM)
Revenue	US$0
Cost of Revenue	US$0
Gross Profit	US$0
Other Expenses	US$0
Earnings	US$0

Last Reported Earnings

n/a

Next Earnings Date

n/a

Earnings per share (EPS)	0
Gross Margin	0.00%
Net Profit Margin	0.00%
Debt/Equity Ratio	0.0%

How did FRNM perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

Data	Last Updated (UTC time)
Company Analysis	2026/07/24 14:03
End of Day Share Price	2026/07/23 00:00
Earnings	N/A
Annual Earnings	N/A

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

Package	Data	Timeframe	Example US Source ^*
Company Financials	10 years	Income statement Cash flow statement Balance sheet	SEC Form 10-K SEC Form 10-Q
Analyst Consensus Estimates	+3 years	Forecast financials Analyst price targets	Analyst Research Reports Blue Matrix
Market Prices	30 years	Stock prices Dividends, Splits and Actions	ICE Market Data SEC Form S-1
Ownership	10 years	Top shareholders Insider trading	SEC Form 4 SEC Form 13D
Management	10 years	Leadership team Board of directors	SEC Form 10-K SEC Form DEF 14A
Key Developments	10 years	Company announcements	SEC Form 8-K

^* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Freenome, Inc. is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

Freenome, Inc.NasdaqCM:FRNM Stock Report